Gandotinib Market In Global
Gandotinib is identified as being highly selective for JAK2-V617F and has advanced into human cli ... Read More
Lestaurtinib inhibits JAK2, FLT3, and TrkA with IC50s of 0.9, 3, and less than 25 nM, respectively. Lestaurtinib is a multi-kinase inhibitor. It also has effective activity against the Trk family of receptor tyrosine kinases.
This report contains market size and forecasts of Lestaurtinib in global, including the following market information:
Global Lestaurtinib Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Lestaurtinib Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Lestaurtinib companies in 2021 (%)
The global Lestaurtinib market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Min Purity Less Than 98% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Lestaurtinib include Bio-Techne, Cayman Chemical, APExBIO Technology, Abcam, BioVision, Merck, Selleck Chemicals, BOC Sciences and TargetMol, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lestaurtinib manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lestaurtinib Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Lestaurtinib Market Segment Percentages, by Type, 2021 (%)
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global Lestaurtinib Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Lestaurtinib Market Segment Percentages, by Application, 2021 (%)
Research
Medical
Global Lestaurtinib Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Lestaurtinib Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lestaurtinib revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Lestaurtinib revenues share in global market, 2021 (%)
Key companies Lestaurtinib sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Lestaurtinib sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bio-Techne
Cayman Chemical
APExBIO Technology
Abcam
BioVision
Merck
Selleck Chemicals
BOC Sciences
TargetMol
MyBiosource
Creative Enzymes
Focus Biomolecules
Hello Bio
Santa Cruz Biotechnology
Biorbyt
StressMarq Biosciences
BioCrick BioTech
Clearsynth
Gandotinib is identified as being highly selective for JAK2-V617F and has advanced into human cli ... Read More
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone (CAS 32384-65-9) is a synthetic building block ... Read More
Pacritinib is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V ... Read More
Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fo ... Read More